TScan Therapeutics Says FDA Granted Regenerative Medicine Advanced Therapy Designation To TSC-100 And TSC-101
TSC-100 and TSC-101 are the Company's two lead TCR-T therapy candidates for the treatment of heme malignancies.
TScan has developed two lead TCR-T therapy candidates, TSC-100 and TSC-101, that target minor histocompatibility antigens HA-1 and HA-2, respectively.